Search Results - "Takifuji, N"

CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer by Masuda, N, Fukuoka, M, Kusunoki, Y, Matsui, K, Takifuji, N, Kudoh, S, Negoro, S, Nishioka, M, Nakagawa, K, Takada, M

“…To evaluate the activity of CPT-11, which is a new derivative of camptothecin, against refractory or relapsed small-cell lung cancer (SCLC). Sixteen patients…”
Get more information

Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer by Negoro, S, Fukuoka, M, Masuda, N, Takada, M, Kusunoki, Y, Matsui, K, Takifuji, N, Kudoh, S, Niitani, H, Taguchi, T

“…7-Ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin (CPT-11) is a novel camptothecin derivative that has been selected for clinical evaluation…”
Get more information

Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer by Masuda, N, Matsui, K, Negoro, S, Takifuji, N, Takeda, K, Yana, T, Kobayashi, M, Hirashima, T, Kusunoki, Y, Ushijima, S, Kawase, I, Tada, T, Sawaguchi, H, Fukuoka, M

“…To determine the response rate, survival, and toxicity of irinotecan (CPT-11), a topoisomerase I inhibitor, combined with etoposide, a topoisomerase II…”
Get more information

CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer by Masuda, N, Fukuoka, M, Takada, M, Kusunoki, Y, Negoro, S, Matsui, K, Kudoh, S, Takifuji, N, Nakagawa, K, Kishimoto, S

“…The purpose of this study was to determine the maximum-tolerated dose and the dose-limiting toxicities of CPT-11, a new derivative of camptothecin, in…”
Get more information

Prognostic factors in elderly patients with unresectable non-small cell lung cancer by Kimura, T, Kudoh, S, Hirata, K, Takifuji, N, Negoro, S, Yoshikawa, J

“…The number of elderly patients with lung cancer is rapidly increasing and their management is an important issue. 109 patients aged over 75 years with…”
Get more information

Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer by MASUDA, N, FUKUOKA, M, NEGORO, S, TAKADA, M, KUDOH, S, KUSUNOKI, Y, MATSUI, K, TAKIFUJI, N, NAKAGAWA, K, TAMANOI, M, NITTA, T, HIRASHIMA, T

“…We have conducted a Phase I trial to determine the maximum tolerated dose of CPT-11 together with a fixed dose of cisplatin in patients with advanced lung…”
Get full text

Dose escalation study of irinotecan combined with carboplatin for advanced non-small-cell lung cancer by TAKEDA, Koji, NEGORO, Shunichi, TAKIFUJI, Nobuhide, NITTA, Takashi, YOSHIMURA, Naruo, TERAKAWA, Kazuhiko, FUKUOKA, Masahiro

“…From December 1994 to July 1997, we conducted a dose escalation study of irinotecan combined with carboplatin in 17 patients with advanced non-small-cell lung…”
Get full text

A randomized trial in inoperable non-small-cell lung cancer: vindesine and cisplatin versus mitomycin, vindesine, and cisplatin versus etoposide and cisplatin alternating with vindesine and mitomycin by Fukuoka, M, Masuda, N, Furuse, K, Negoro, S, Takada, M, Matsui, K, Takifuji, N, Kudoh, S, Kawahara, M, Ogawara, M

“…Patients with inoperable non-small-cell lung cancer (NSCLC) were randomly assigned to receive one of three dosage regimens: (1) vindesine and cisplatin (VP);…”
Get more information

A prospective phase II study on photodynamic therapy with photofrin II for centrally located early-stage lung cancer. The Japan Lung Cancer Photodynamic Therapy Study Group by Furuse, K, Fukuoka, M, Kato, H, Horai, T, Kubota, K, Kodama, N, Kusunoki, Y, Takifuji, N, Okunaka, T, Konaka, C

“…A phase II study was conducted between June 1989 and February 1992 to evaluate the activity and toxicity of photodynamic therapy (PDT) with photofrin II in…”
Get more information

Establishment of tumor cell lines as an independent prognostic factor for survival time in patients with small-cell lung cancer by Masuda, N, Fukuoka, M, Matsui, K, Kusunoki, Y, Kudoh, S, Negoro, S, Takifuji, N, Fujisue, M, Morino, H, Nakagawa, K

“…We studied tumor samples from 39 patients, who entered our study from January 1989 to May 1990, to assess whether the ability to establish a continually…”
Get more information

Mitomycin C, vindesine, and cisplatin in advanced non-small-cell lung cancer. A phase II study by Fukuoka, M, Negoro, S, Masuda, N, Kusunoki, Y, Matsui, K, Ryu, S, Takifuji, N, Kudoh, S, Takada, M

“…Between August 1985 and June 1986, 49 previously untreated patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) were treated with…”
Get more information

Combination therapy with bestatin in inoperable lung cancer. A randomized trial by Takada, M, Fukuoka, M, Negoro, S, Kusunoki, Y, Matsui, K, Masuda, N, Sakai, N, Ryu, S, Takifuji, N, Kudo, S

“…A randomized trial of combination therapy with bestatin (30 mg daily, every day) was performed in 238 patients with inoperable primary lung cancer from August,…”
Get more information

Redevelopment of small-cell lung cancer nine years after the start of therapy. A case report and review of the literature by Masuda, N, Fukuoka, M, Takada, M, Negoro, S, Matsui, K, Takifuji, N, Kudoh, S, Kazunobu, I, Nakagawa, K, Kusunoki, Y

“…Most patients with small-cell lung cancer usually relapse within 1 to 2 years. Relapses after a 5-year disease-free interval occur extremely rarely. This…”
Get more information

Japanese experience with second-line chemotherapy with low-dose (60 mg/m2) docetaxel in patients with advanced non-small-cell lung cancer by MUKOHARA, Toru, TAKEDA, Koji, MIYAZAKI, Masaki, TAKIFUJI, Nobuhide, TERAKAWA, Kazuhiko, NEGORO, Shunichi

“…To assess the efficacy and toxicity of relatively low-dose docetaxel (60 mg/m2) for previously treated advanced non-small-cell lung cancer (NSCLC). Patients…”
Get full text

Studies on the appropriate administration of cisplatin based on pharmacokinetics and toxicity by Kitajima, K, Fukuoka, M, Kobayashi, S, Kusunoki, Y, Takada, M, Negoro, S, Matsui, K, Sakai, N, Ryu, S, Takifuji, N

“…Ninety-six patients with non-small cell lung cancer were treated with cisplatin (80-150 mg/m2). The pharmacokinetics of cisplatin were studied in 27 of these…”
Get more information

P-955 Clinicopathological features and efficacy of gefitinib in patients with non-small cell lung cancer (NSCLC) — Comparison between adenocarcinoma and non-adenocarcinoma by Kawano, Y., Kashii, T., Katayama, H., Hasegawa, Y., Tokunaga, S., Sumitani, M., Takeda, K., Takifuji, N., Nakajima, R., Tada, H.

Get full text

Prognostic factors affecting survival and response in patients with advanced non-small cell lung cancer treated with combination chemotherapy by Takifuji, N, Fukuoka, M, Negoro, S, Takada, M, Kusunoki, Y, Matsui, K, Masuda, N, Ryu, S, Sakai, N, Kubota, K

“…One-hundred and ninety-nine patients who had an inoperable stage III or IV non-small cell lung cancer (NSCLC) and collected were analyzed on the basis of…”
Get more information

Thoracoscopic pleural biopsy under local anesthesia using a 2 mm laparoscope by Ikeda, N, Tada, H, Yamamoto, R, Kishi, A, Tojo, T, Negoro, S, Terakawa, K, Takifuji, N, Takeda, K, Iioka, S

“…Thoracoscopy is indicated in patients with undiagnosed effusion after conventional methods. It has been usually performed under general anesthesia or using a…”
Get more information

Serial measurements of serum carcinoembryonic antigen (CEA) and neuron-specific enolase (NSE) during chemotherapy of patients with inoperable lung cancer by Fukuoka, M, Takada, M, Kamei, T, Negoro, S, Kusunoki, Y, Matsui, K, Ryu, S, Sakai, N, Takifuji, N, Masuda, N

“…Serial measurements of serum CEA levels were analyzed in 226 patients with inoperable lung cancer (115 small cell carcinomas, 64 adenocarcinomas, 37 squamous…”
Get more information

Phase II study of irinotecan and carboplatin for advanced non-small cell lung cancer by Takeda, Koji, Takifuji, Nobuhide, Uejima, Hisao, Yoshimura, Naruo, Terakawa, Kazuhiko, Negoro, Shunichi

“…A phase II study was conducted to assess the activity and toxicity of irinotecan (CPT-11) and carboplatin (CBDCA) combination chemotherapy for advanced…”
Get full text